doi: 10.3109/01913123.2011.606659
Disclosures: Antonio Moreno: Nothing to Disclose, Thomas Issa: Nothing to Disclose, Douglas Farmer: Nothing to Disclose, Edward Wolfgang Lee: Nothing to Disclose 2224 STATIN USE IN CIRRHOSIS CAN DECREASE RISK OF PORTAL HYPERTENSION AND MORTALITY Muhammad Ali Butt 1 Taimur Muzammil 1 Rahul Karna 2 Himsikhar Khataniar 1 Nabeeha Mohy-ud-din 3 , 1 Allegheny General Hospital, Pittsburgh, PA, 2 University of Minnesota Medical Center, 3 Division of Gastroenterology, Hepatology and Nutrition, Allegheny Health Network, Pittsburgh, PA Background: MASLD related cirrhosis is one of the leading etiologies of liver disease, and these patients frequently have other comorbidities like atherosclerotic cardiovascular disease (ASCVD), hyperlipidemia (HLD), cerebrovascular disease (CVD), and diabetes mellitus (DM)
Rojas-Rivera, D
RBS design was aided by RBS Calculator (version 2.0, Construction of genomic replacement mutants of C